Oncopharmpod
It's All Immunotherapy Nowadays
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:17:23
- More information
Informações:
Synopsis
Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.
